Science News

Diagnosis Of Cutaneous Leishmaniasis Improved With New Techniques

ScienceDaily (Jan. 29, 2008) — Dutch researcher Wendy van der Meide has developed and evaluated new techniques for a better diagnosis of cutaneous leishmaniasis and an improved monitoring of its treatment. Accurately establishing the number of parasites in a skin lesion before, during and after treatment is vital, so as to prevent serious physical consequences.

Cutaneous leishmaniasis (CL) is a non-lethal disease but can have grave consequences for the patient. Such consequences can be prevented with a rapid and accurate diagnosis and treatment. The treatment is based on clinical criteria. Therefore, it is essential to establish the number of parasites present in a skin lesion as accurately as possible before, during and after treatment in order to assess the treatment outcome.

Van der Meide has developed and evaluated a technique for the detection and quantification of Leishmania parasites. The so-called QT-NASBA technique, based on recognition of nucleic acids of the parasite, was found to be a sensitive and specific tool for monitoring treatments. The instrument can also contribute to predicting the clinical outcome. Although QT-NASBA was highly sensitive, another technique, the so-called real-time Reverse Transcriptase PCR was found to be more suitable due to its greater time efficiency and lower costs.

In practice, neither of these two techniques will be quickly deployed in developing countries. Therefore, different antigens were also compared in a serological test (ELISA) for use in Brazil and Suriname, where the disease is mainly caused by Leishmania guyanensis. The use of antigens for this species of Leishmania significantly improved the serological test compared to antigens from other species. These results could be vitally important for improving the effectiveness of serological tests for the diagnosis of CL.

Part of the research was carried out in Suriname. Van der Meide discovered that the prescribed treatment was only carried out to completion in a low percentage of cases; just half of the CL patients received the full treatment. Moreover, fewer patients seemed to recover than had previously been observed. Consequently, a shorter and more efficient treatment protocol was recommended to improve the use and efficacy of the treatment. Furthermore, it was demonstrated that not one but three different species of Leishmania in Suriname can cause human infection.

Parasites

Leishmaniasis is an infectious disease caused by single-celled parasites transmitted by sand flies. The disease occurs in tropical regions in Africa, Asia and America but also in the Mediterranean region and in the Middle East. Worldwide there is a clear and disturbing increase in the number of CL patients. CL results in one or more skin sores, and in the case of L. guyanensis regularly spreads into the lymph vessels. Although the sores can spontaneously disappear over the course of several months or years, they leave severe scars behind. Some types of CL can spread into the mucous membranes. This can lead to considerable damage of the nose cartilage and mouth.


Adapted from materials provided by Netherlands Organization for Scientific Research.
Email or share this story:
| More
APA

MLA

Search ScienceDaily

Number of stories in archives: 44,032

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.
 

Science Video News


New Test For Chronic Cough

Pulmonologists have found that a diagnostic test for asthma--the exhaled nitric oxide test is a quick and easy way to determine whether inhaled. ...  > full story

Breaking News

... from NewsDaily.com

In Other News ...

Copyright Reuters 2008. See Restrictions.

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of the new ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Post this page to your favorite social bookmarking site:
close
Include this item in your blog or web site:
close
Cite this article in your essay, paper, or report:
close
Email this page's link to a friend or colleague:
close